Moderna maintains vaccine sales view as demand from low-income nations eases

Published by

(Reuters) – Moderna Inc on Wednesday retained its full-year sales outlook for COVID-19 shot at $21 billion due to decreasing orders from low- and middle-income countries through the COVAX international vaccine-sharing program. The unchanged forecast came despite Moderna’s $1.74 billion deal last week with the U.S. government for 66 million doses of a vaccine updated for Omicron subvariants. “It’s because of COVAX. As you remember, we have a partnership with COVAX to supply product to low-income countries. COVAX does not want the doses that they have ordered,” Chief Executive Stephane Bancel to…

Read More

Leave a Reply